Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phibro Animal Health (PAHC) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Phibro Animal Health (PAHC) over the last 13 years, with Q4 2025 value amounting to $55.5 million.

  • Phibro Animal Health's Cash & Equivalents fell 1727.64% to $55.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $55.5 million, marking a year-over-year decrease of 1727.64%. This contributed to the annual value of $68.0 million for FY2025, which is 364.52% down from last year.
  • As of Q4 2025, Phibro Animal Health's Cash & Equivalents stood at $55.5 million, which was down 1727.64% from $72.8 million recorded in Q3 2025.
  • In the past 5 years, Phibro Animal Health's Cash & Equivalents ranged from a high of $76.3 million in Q3 2022 and a low of $33.0 million during Q4 2023
  • For the 5-year period, Phibro Animal Health's Cash & Equivalents averaged around $57.2 million, with its median value being $57.9 million (2025).
  • In the last 5 years, Phibro Animal Health's Cash & Equivalents crashed by 5181.37% in 2023 and then surged by 10343.95% in 2024.
  • Quarter analysis of 5 years shows Phibro Animal Health's Cash & Equivalents stood at $63.4 million in 2021, then grew by 7.95% to $68.4 million in 2022, then crashed by 51.81% to $33.0 million in 2023, then soared by 103.44% to $67.1 million in 2024, then dropped by 17.28% to $55.5 million in 2025.
  • Its Cash & Equivalents stands at $55.5 million for Q4 2025, versus $72.8 million for Q3 2025 and $68.0 million for Q2 2025.